14:36 Tue 17 Sep 2019
Qrons Inc (OTCQB: QRON) CEO Jonah Meer tells Proactive the New York-based biotechnology company is developing two products, one of which involves a 3D-printable scaffold, aimed at helping to treat traumatic brain injuries.
Meer says that traumatic brain injuries are the number one cause of death among young adults in the US, adding that the company is working towards an Investigational New Drug application or a Biologics Licence application for its products to the FDA.
Price: 0.4 USD
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
FOR OUR FULL DISCLAIMER CLICK HERE
Algernon Pharmaceuticals Inc. (CSE: AGN-OTCQB: AGNPF) CEO Christopher Moreau joined Steve Darling from Proactive Vancouver with major news for the company that they have received clearance from the U.S. FDA for its multinational Phase 2b/3 study of Ifenprodil as a potential treatment for...
Retail & consumer
Mining
Health
